0.7 for sensitivity and >0.68 for specificity, for 2 independent readers to declare the study positive. [3]Note: representative patient response only, may not be representative for all patients. [4]ASX disclosure 20 December 2021. [5]ASX disclosure 2 November 2021. [6]ASX disclosure 14 October 2022. Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Corporate Communications and Investor Relations Email: [email protected] Legal Notice This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website. 2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved)."/> 0.7 for sensitivity and >0.68 for specificity, for 2 independent readers to declare the study positive. [3]Note: representative patient response only, may not be representative for all patients. [4]ASX disclosure 20 December 2021. [5]ASX disclosure 2 November 2021. [6]ASX disclosure 14 October 2022. Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Corporate Communications and Investor Relations Email: [email protected] Legal Notice This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website. 2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved)."/> 0.7 for sensitivity and >0.68 for specificity, for 2 independent readers to declare the study positive. [3]Note: representative patient response only, may not be representative for all patients. [4]ASX disclosure 20 December 2021. [5]ASX disclosure 2 November 2021. [6]ASX disclosure 14 October 2022. Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Corporate Communications and Investor Relations Email: [email protected] Legal Notice This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website. 2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved)." /> 0.7 for sensitivity and >0.68 for specificity, for 2 independent readers to declare the study positive. [3]Note: representative patient response only, may not be representative for all patients. [4]ASX disclosure 20 December 2021. [5]ASX disclosure 2 November 2021. [6]ASX disclosure 14 October 2022. Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Corporate Communications and Investor Relations Email: [email protected] Legal Notice This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website. 2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved)." />

Watch latest videos

News RELEASES

Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Singapore Star.

More Information
null in null

International

Section
AstraZeneca pill slows cancer when guided by early blood test
Blood test-guided therapy halves breast cancer progression risk

CHICAGO, Illinois: A simple blood test could help breast cancer patients get the proper treatment earlier, potentially halving their...

Czech minister quits after ministry sells $45 million in bitcoins
Czech justice minister resigns over a donated bitcoin scandal

PRAGUE, Czech Republic: Czech Justice Minister Pavel Blažek resigned this week because of a scandal involving bitcoins. Earlier this...

Hegseth reassures Indo-Pacific Allies: 'You won’t face China alone'
US vows support for Indo-Pacific against China's rising pressure

SINGAPORE: On May 31, U.S. Defense Secretary Pete Hegseth told America's Indo-Pacific allies that they would not be left alone to deal...

Gazan aid centers described by UN as "death traps"
Casualties mount as Israeli troops continue firing on Gazans seeking aid

JERUSALEM (CNN) - Palestinians on their way to receive aid from a distribution site in southern Gaza have come under fire for a third...

U.S.-China tensions flare again as Trump threatens tougher stance
Trump accuses China of violating Geneva trade truce on tariffs

WASHINGTON, D.C.: Tensions reignite in the U.S.-China trade truce after President Donald Trump accused Beijing of violating a recent...

UN faces $3.7 billion budget trim, staff cuts amid funding crisis
UN plans 20 percent budget cut, may slash nearly 7,000 jobs

NEW YORK CITY, New York: Facing a deepening financial crisis, the United Nations Secretariat is planning to cut 20 percent of its US$3.7...

Business

Section
U.S. stock markets diverge as economic data disappoints
Wall Street ends mixed after disappointing ADP report

NEW YORK, New York -  U.S. stocks were mixed Wednesday as investors and traders grappled with the ADP report, which revealed payrolls...

Steering defect forces Ford to recall 29K electric trucks in US
Ford recalls 29,000 F-150 Lightning e-trucks for steering control flaw

DEARBORN, Michigan: Ford is pulling back tens of thousands of its electric pickup trucks over a steering defect that could lead to...

Best Buy warns of slower growth amid tariff and economic worries
Best Buy lowers outlook as tariff worries and weak sales hit business

NEW YORK CITY, New York: Best Buy, the biggest electronics store chain in the U.S., has lowered its forecast for the year. The company...

Costco delays imports to dodge tariffs, won’t raise prices yet
Costco misses revenue estimates but holds off on price hikes

ISSAQUAH, Washington: Costco is feeling the pinch from tariffs and soft consumer spending, missing Wall Street's revenue expectations...

U.S. stock markets close higher as techs surge
Dow Jones adds 214 points as U.S. stocks rally

NEW YORK, New York - U.S. stocks closed higher on Tuesday as the markets continues to ebb and flow on prouncements and moves by the...

Investors stare down trade tensions, soft factory data, oil rally
U.S. and global economies facing challenging times

NEW YORK CITY, New York: Weak U.S. manufacturing data, renewed tariff concerns, and rising oil prices are giving investors plenty to...

Movie Review